CIK 0001719714 · Non-accelerated filer<br>Smaller reporting company
Mereo BioPharma Group plc
Sign in to watch- Ticker
- MREO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 4403330237300
- Business address
- ONE CAVENDISH PLACE, FOURTH FLOOR, LONDON, United Kingdom, W1G 0QF
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-01 | Sermon Charles General Counsel | Grant or award · Share Options (Right to buy) | +315,750 | 315,750 | ||
| 2026-02-01 | Sermon Charles General Counsel | Grant or award · Share Options (Right to buy) | +105,250 | 105,250 | ||
| 2026-02-01 | Sermon Charles General Counsel | Grant or award · Share Options (Right to buy) | +295,000 | 295,000 | ||
| 2026-02-01 | Scots-Knight Denise Chief Executive Officer | Grant or award · Share Options (Right to buy) | +1,035,000 | 1,035,000 | ||
| 2026-02-01 | Scots-Knight Denise Chief Executive Officer | Grant or award · Share Options (Right to buy) | +345,000 | 345,000 | ||
| 2026-02-01 | Scots-Knight Denise Chief Executive Officer | Grant or award · Share Options (Right to buy) | +480,000 | 480,000 | ||
| 2026-02-01 | Fox Christine Ann Chief Financial Officer | Grant or award · Share Options (Right to buy) | +315,750 | 315,750 | ||
| 2026-02-01 | Fox Christine Ann Chief Financial Officer | Grant or award · Share Options (Right to buy) | +105,250 | 105,250 | ||
| 2026-02-01 | Fox Christine Ann Chief Financial Officer | Grant or award · Share Options (Right to buy) | +280,000 | 280,000 | ||
| 2025-02-05 | Bender Jeremy Director | Grant or award · Share Options (Right to buy) | +55,000 | 55,000 | ||
| 2025-02-05 | Bender Jeremy Director | Grant or award · Deferred Restricted Stock Units | +16,768 | 16,768 | ||
| 2025-02-05 | Shames Daniel Director | Grant or award · Share Options (Right to buy) | +55,000 | 55,000 | ||
| 2025-02-05 | Shames Daniel Director | Grant or award · Deferred Restricted Stock Units | +13,719 | 13,719 | ||
| 2025-02-05 | Jacquet Pierre Director | Grant or award · Share Options (Right to buy) | +55,000 | 55,000 | ||
| 2025-02-05 | Jacquet Pierre Director | Grant or award · Deferred Restricted Stock Units | +15,243 | 15,243 | ||
| 2025-02-05 | Yoskowitz Marc J Director | Grant or award · Share Options (Right to buy) | +55,000 | 55,000 | ||
| 2025-02-05 | Yoskowitz Marc J Director | Grant or award · Deferred Restricted Stock Units | +13,719 | 13,719 | ||
| 2025-02-05 | PAKIANATHAN DEEPIKA Director | Grant or award · Share Options (Right to buy) | +55,000 | 55,000 | ||
| 2025-02-05 | Ekblom Anders Director | Grant or award · Share Options (Right to buy) | +55,000 | 55,000 | ||
| 2025-02-05 | Ekblom Anders Director | Grant or award · Deferred Restricted Stock Units | +19,054 | 19,054 |
Page 2 of 7 · 139 trades